Potential breakthrough for T-Cell lymphoma patients with drug that mimics folic acid

Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).

Read the whole article on Physorg

More from Physorg